Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 301 to 310 of 1338 total matches.

Tramadol - A New Oral Analgesic

   
The Medical Letter on Drugs and Therapeutics • Jul 07, 1995  (Issue 952)
Administration for oral treatment of moderate to moderately severe pain. Despite some opioid activity, tramadol ...
Tramadol hydrochloride (Ultram - Ortho-McNeil), a centrally-acting analgesic marketed in Germany since 1977, was recently approved by the US Food and Drug Administration for oral treatment of moderate to moderately severe pain. Despite some opioid activity, tramadol has not been scheduled as a controlled substance.
Med Lett Drugs Ther. 1995 Jul 7;37(952):59-60 |  Show IntroductionHide Introduction

Beta-Adrenergic Blockers and Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2012  (Issue 1382)
. No prospective, randomized trials have been published.1 MECHANISM OF ACTION — Activation of the betaadrenergic ...
Three retrospective studies have recently reported an association between beta-blocker use and a reduction in breast cancer metastasis and recurrence. No prospective, randomized trials have been published.
Med Lett Drugs Ther. 2012 Jan 23;54(1382):6-7 |  Show IntroductionHide Introduction

Vismodegib (Erivedge) for Basal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
pathway are thought to be the cause of basal cell carcinoma.2 Vismodegib inhibits the signaling activity ...
The FDA has approved vismodegib (vis moe deg´ ib; Erivedge – Genentech), the first hedgehog (Hh) pathway inhibitor, for oral treatment of metastatic basal cell cancer, locally advanced basal cell carcinoma that has recurred after surgery, or locally advanced basal cell carcinoma in adults who are not candidates for surgery or radiation.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4 |  Show IntroductionHide Introduction

Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa

   
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018  (Issue 1553)
concentrations achieved with topical therapy.5 Other topical antimicrobials that are active against both ...
The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin (Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by Pseudomonas aeruginosa or Staphylococcus aureus in patients ≥6 months old. Otiprio was approved earlier for prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement.
Med Lett Drugs Ther. 2018 Aug 13;60(1553):135-6 |  Show IntroductionHide Introduction

Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
- associated pneumonia caused by susceptible gram- negative organisms, including ABC. ACTIVITY ― Sulbactam ...
The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90   doi:10.58347/tml.2023.1690c |  Show IntroductionHide Introduction

Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
glioma harboring an activating RAF alteration is ongoing. ADVERSE EFFECTS — In the FIREFLY-1 trial ...
Tovorafenib (Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or a BRAF V600 mutation. Tovorafenib is the first systemic treatment to be approved in the US for pediatric low-grade gliomas with BRAF fusions. Accelerated approval of tovorafenib was based on response rates and duration of response.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):e97-8   doi:10.58347/tml.2024.1704f |  Show IntroductionHide Introduction

Saxagliptin (Onglyza) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
hrs (active metabolite) Metabolism Hepatic by CYP3A4/5 to active metabolite (half as potent ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Med Lett Drugs Ther. 2009 Nov 2;51(1324):85-6 |  Show IntroductionHide Introduction

Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
stability against beta-lactamases.4,5 SPECTRUM OF ACTIVITY — Cefiderocol has no clinically relevant ...
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Med Lett Drugs Ther. 2020 May 4;62(1597):65-8 |  Show IntroductionHide Introduction

Pharmaceutical Drug Overdose

   
Treatment Guidelines from The Medical Letter • Sep 01, 2006  (Issue 49)
pneumonia. Perforation of the esophagus, laryngospasm and hypoxia can occur. Activated charcoal (AC ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Treat Guidel Med Lett. 2006 Sep;4(49):61-6 |  Show IntroductionHide Introduction

Timing of Remdesivir for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
analog that inhibits viral replication by binding to RNA-dependent RNA polymerase. It is active against ...
Remdesivir (Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use of the drug to patients hospitalized with severe disease.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):161 |  Show IntroductionHide Introduction